Ingevity (NGVT)
(Delayed Data from NYSE)
$45.15 USD
+0.71 (1.60%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $45.14 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
$45.15 USD
+0.71 (1.60%)
Updated Jul 22, 2024 04:00 PM ET
After-Market: $45.14 -0.01 (-0.02%) 7:58 PM ET
3-Hold of 5 3
B Value C Growth F Momentum C VGM
Zacks News
Venator (VNTR) Surges: Stock Moves 6.9% Higher
by Zacks Equity Research
Venator (VNTR) saw a big move last session, as its shares jumped nearly 7% on the day, amid huge volumes.
4 Chemical Specialty Stocks to Escape Industry Challenges
by Anindya Barman
Soft demand amid sluggish industrial activities due to coronavirus clouds prospects for the Zacks Chemicals Specialty industry. Quaker Chemical (KWR), Valvoline (VVV), Element Solutions (ESI) and Ingevity (NGVT) are set to gain from self-help actions.
Ingevity (NGVT) Up 12% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Ingevity (NGVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Why You Should Add Ingevity (NGVT) Stock to Your Portfolio
by Zacks Equity Research
Ingevity (NGVT) benefits from regulation-driven adoption of its applications and cost-reduction measures.
Ingevity (NGVT) Q3 Earnings and Revenues Beat Estimates
by Zacks Equity Research
Ingevity (NGVT) delivered earnings and revenue surprises of 82.65% and 6.71%, respectively, for the quarter ended September 2020. Do the numbers hold clues to what lies ahead for the stock?
Ingevity (NGVT) Up 44% in 6 Months: What's Behind the Rally?
by Zacks Equity Research
Ingevity (NGVT) benefits from its cost-management actions and regulation-driven demand for its applications.
Ingevity Gains on Cost Actions Amid Weak Industrial Demand
by Anindya Barman
Ingevity (NGVT) benefits from cost-reduction measures and growth in its applications driven by regulations and technology adoption.
Why You Should Keep Ingevity (NGVT) Stock in Your Portfolio
by Zacks Equity Research
While Ingevity (NGVT) faces headwind from soft demand in industrial specialties and oilfield technologies, it should gain from cost actions and regulation-driven adoption of its applications.
Ingevity (NGVT) Up 57% in 6 Months: What's Driving the Stock?
by Zacks Equity Research
Ingevity (NGVT) benefits from its cost-saving actions and growth in its applications driven by regulations and technology adoption.
Why Is Ingevity Corporation (NGVT) Up 1.4% Since Last Earnings Report?
by Zacks Equity Research
Ingevity Corporation (NGVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Here's Why You Should Hold Onto Ingevity (NGVT) Stock for Now
by Zacks Equity Research
While Ingevity (NGVT) is exposed to weakness in industrial specialties and oilfield technologies businesses, it should gain from strong demand for activated carbon products in China and cost actions.
Ingevity (NGVT) Earnings Meet, Sales Beat Estimates in Q2
by Zacks Equity Research
Ingevity's (NGVT) Q2 revenues decline year over year on account of weaker demand, fuelled by the economic impacts of the coronavirus pandemic.
Ingevity Corporation (NGVT) Matches Q2 Earnings Estimates
by Zacks Equity Research
Ingevity Corporation (NGVT) delivered earnings and revenue surprises of 0.00% and 7.77%, respectively, for the quarter ended June 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Ingevity Corporation (NGVT) Q2 Earnings Expected to Decline
by Zacks Equity Research
Ingevity Corporation (NGVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Chemical Specialty Industry Outlook Bleak on Muted Demand
by Anindya Barman
Weak demand and raw material supply disruptions due to coronavirus pose as headwinds to the chemical specialty industry.
Why You Should Retain Ingevity (NGVT) Stock in Your Portfolio
by Zacks Equity Research
While Ingevity (NGVT) is exposed to weakness in industrial specialties, it should gain from the Capa acquisition.
Ingevity to Lower Costs in Response to Coronavirus Outbreak
by Zacks Equity Research
Ingevity's (NGVT) cost-reduction measures will allow it to stay within the revised guidance range set out in its earnings release for the first quarter of 2020.
Ingevity Corporation (NGVT) Up 3.1% Since Last Earnings Report: Can It Continue?
by Zacks Equity Research
Ingevity Corporation (NGVT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Ingevity Gains on Capa Buyout Amid Weak Industrial Demand
by Zacks Equity Research
While Ingevity (NGVT) is exposed to weakness in industrial specialties, it is gaining from the Capa acquisition.
Ingevity (NGVT) Earnings & Revenues Surpass Estimates in Q1
by Zacks Equity Research
Ingevity (NGVT) expects sales for 2020 to be between $1.1 billion and $1.2 billion.
Ingevity Corporation (NGVT) Beats Q1 Earnings and Revenue Estimates
by Zacks Equity Research
Ingevity Corporation (NGVT) delivered earnings and revenue surprises of 33.33% and 9.99%, respectively, for the quarter ended March 2020. Do the numbers hold clues to what lies ahead for the stock?
Earnings Preview: Ingevity Corporation (NGVT) Q1 Earnings Expected to Decline
by Zacks Equity Research
Ingevity Corporation (NGVT) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Ingevity to Gain From Capa Buyout & Regulation-driven Demand
by Zacks Equity Research
While Ingevity (NGVT) is exposed to cost pressures, and weakness in industrial specialties and oilfield applications, it should gain from the Capa acquisition.
Here's Why You Should Hold Onto Ingevity (NGVT) Stock Now
by Zacks Equity Research
Let's find out why specialty chemicals and materials maker Ingevity (NGVT) is worth retaining at the moment.
Ingevity Provides Update in Response to Coronavirus Outbreak
by Zacks Equity Research
Ingevity's (NGVT) first quarter is going better than anticipated despite modest headwinds from the coronavirus outbreak.